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Abstract. Screening procedures for chromosomal abnormalities in fetuses are a standard of care for pregnant 
women. Ultrasound and maternal serum analysis are traditional prenatal screening methods with detection rates 
between 75%-95%, and considerable false-negative and false-positive results. Also, both require follow up by invasive 
diagnostic tests in screen-positive cases, mostly amniocentesis and chorionic villi sampling, which are associated with 
notable risk of pregnancy loss. One of the innovative non-invasive prenatal testing (NIPT) options is the analysis of 
cell-free DNA (cfDNA) in plasma, which is detected in maternal circulation in a relatively high concentration. 
Commercial tests for cfDNA in maternal blood have recently become available. Cell-free DNA detection tests do not 
separate fetal from maternal DNA but use full cfDNA complement and analyze difference in total amount of sequenced 
DNA fragments, with the help of sophisticated data analysis software. It seems that cfDNA technology testing is highly 
accurate and has a very high sensitivity, so the difference compared to routine serum sample screening shows its 
significant superiority. However, cfDNA positive results still need confirmation by the invasive testing. The cell-free 
DNA analysis aims to become the first choice NIPT option due to its safety and high accuracy rate. The final goal is to 
develop the reliable method that could eventually replace invasive prenatal testing procedures. 




A standard care for pregnant women includes the use of 
prenatal diagnostic tests. Screening procedures are done 
early in pregnancy in order to identify the presence of 
chromosomal abnormalities, especially aneuploidies. 
These anomalies are the most common factor causing the 
failure of an embryo’s growth and normal development of 
fetus. The most frequent chromosome abnormalities 
in miscarriages include trisomy or monosomy for 
chromosomes 13 (Patau syndrome, T13), 15, 16, 18 
(Edwards syndrome, T18), 21 (Down syndrome, T21), or 
22, as well as triploidy and abnormalities of sex 
chromosomes. Most fetuses with aneuploidies succumb to 
an early miscarriage, and only few percent survive to the 
newborn period, but may suffer significant morbidity and 
mortality [1,2]. 
The prenatal diagnostic techniques comprise non-
invasive diagnostics - ultrasonography (nuchal 
translucency) and maternal serum screening (alpha-
fetoprotein, estriol, beta-hCG) and invasive diagnostic 
methods - amniocentesis (AC) and chorionic villus 
sampling test (CVS). Ultrasound and maternal serum 
analysis are considered to be screening procedures that 
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both require follow up by CVS or AC in screen-positive 
cases for a definitive diagnosis of a chromosome 
abnormality in the fetus. Invasive procedures are 
associated with notable risk of pregnancy loss, thus most 
female do not undergo the procedures unless there is a high 
risk indication. Invasive prenatal diagnosis is not a feasible 
option for all low-risk mothers and would eventually cause 
more miscarriages than detection of aneuploidy [35]. 
In order to improve the efficiency of non-invasive 
prenatal diagnostics and reduce the risk of currently 
available invasive procedures, the creation of novel, 
more sophisticated methods is of primary importance. 
Considerable effort has been devoted to developing a 
more accurate, reliable and safe non-invasive prenatal 
testing (NIPT), that would have a high detection rate 
(~95%) and low false-positive rate (~1%) [2]. 
In 2012 the American Congress of Obstetricians and 
Gynecologists (ACOG) approved the use of noninvasive 
testing of cell-free fetal DNA (cfDNA) in maternal 
circulation for women at high risk [6]. Since then, 
numerous reports on the use of cfDNA for NIPT have been 
published, and a number of commercial products were 
created [7]. 
Prenatal tests using cfDNA analysis are especially 
suitable for detection of chromosomal aneuploidies, 
trisomy or monosomy. Sex chromosomes aneuploidies 
(45, X0 - Turner syndrome, XXY – Klinefelter syndrome, 
and triple X syndrome) can also be detected with this 
method [2]. 
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The objective of this review is to present current 
knowledge and describe newly developed methods for 
application of cfDNA detection and analysis as the new 
NIPT option. 
Traditional Prenatal Screening Methods 
Non-invasive prenatal screening, recommended by the 
ACOG and the American College of Medical Genetics, 
includes a combination of first trimester risk assessment 
(FTRA) [11-14 weeks), maternal serum analyte (quad) 
screening (15-20 weeks), and a sonographic fetal 
structural survey (18-22 weeks). These tests are safe for 
the pregnancy but their primary target is detection of 
T21. The first trimester risk assessment and quad 
screening generally provide an adjusted risk for the 
presence of fetal aneuploidy. A sonographic fetal survey 
may suggest fetal aneuploidy by identifying so-called 
soft markers, with greater accuracy if several of these 
markers are present [3,5,8]. 
Detection rates of traditional prenatal screening 
methods are between 75% and 96% with considerable 
false-negative rates between 12-23% and false-positive 
rates ranging from 5% to 10%. If the results are 
positive, further checkup and confirmation is needed by 
direct genetic testing [3,5,811]. 
A definitive prenatal diagnosis of fetal aneuploidy 
requires direct fetal cells karyotyping and genetic analysis, 
for which two invasive procedures are routinely applied: 
CVS and AC. For CVS, a biopsy of placental cells is 
employed. The procedure can be performed early in 
pregnancy (10-13 weeks) and the results are issued within 
the following 10 days. Besides its invasiveness, the 
problem with CVS lies in the cell type which is sampled 
for the analysis, as these cells originate from the 
trophoectoderm and may contain placental mosaicism 
[2,12]. For AC, the primarily derived fetal cells are gained 
by aspiration of amniotic fluid and further subjected to 
analysis. Given the high pregnancy loss rates in early AC, 
it is usually offered after 15 weeks of gestation. Also, a low 
number of harvested cells require longer culture times and 
thus results can be issued within 8-14 days [2,13]. 
The diagnostic accuracy of karyotyping for specified 
invasive tests was found to be 97.5% to 99.8% [14,15]. 
Estimation of procedure-related miscarriage risk is 1% 
for CVS, while AC is regarded as a safer procedure with 
1/300 to 1/600 risk [4,5,16-18]. In 2015, Akolekar et al. 
[19] reported in a systematic meta-analysis that the 
procedure-related risks of miscarriage for these invasive 
procedures are 0.81% and 2.18% for AC and CVS, 
respectively. 
Cytogenetic analyses, ensuing invasive procedures, 
comprise fluorescence in situ hybridization (FISH) 
method and chromosomal microarray analysis (CMA). 
With FISH method, the results are available within 24 to 
48 hours. The sensitivity and specificity of FISH is 
estimated between 99.6% and 99.98%. Disadvantage of 
the method is that it identifies only the most frequent 
cytogenetic abnormalities, thus the FISH should always 
be followed by routine chromosome analysis [20]. Besides 
detection of chromosome number abnormalities, CMA 
testing provides results for chromosomal imbalances 
(copy number variants) such as microdeletions and 
microduplications and unbalanced rearrangements of 
chromosome segments [21,22]. 
Fetal Cells and Cell-free DNA  
in Prenatal Diagnostics 
At first, analysis of fetal cells in maternal blood was 
considered as a promising new candidate for non-
invasive prenatal diagnostics. The possibility of their 
isolation and study for early chromosomal abnormalities 
in the first and second trimester provided exciting new 
opportunities for NIPT [2]. 
During pregnancy, fetal and maternal cells are 
exchanged across placenta [23]. It is suggested that this 
process has a physiological role in the development of 
maternal tolerance to the fetus. The precise mechanism 
by which this occurs is still unclear. Some of the 
proposed mechanisms include micro-traumatic rupture 
of the placental blood channels or leakage of placenta-
uterine barrier, adhesion and transmigration across high 
endothelial venulae, and other [24,25].  
There are several types of fetal cells detected in 
maternal blood during pregnancy. Cells that are most 
frequently found and examined are nucleated red blood 
cells or erythroblasts, CD34+ hematopoietic progenitors, 
trophoblasts, lymphocytes, and granulocytes. A 
fetomaternal microchimerism created in this way may 
persist for the lifetime [26,27]. 
However, there are specific disadvantages in 
management of all these cell types [26]. The major 
problem for successful usage of the cells is their scarcity in 





cells after the first trimester). This requires special 
techniques for their enrichment in maternal blood sample 
before any further analysis. Many different cell isolation 
methods have been developed in order to obtain the 
successful quantity of fetal cells (flow cytometry, density 
gradient centrifugation, micromanipulation), but all the 
methods require high technical approaches and still provide 
low yield [2, 28]. 
However, it was shown in 1997 that fetal cell-free 
DNA could be detected in maternal circulation, with 
relatively high mean concentration in total plasma DNA 
(3.4%-6.2%). This is 20 to 25 times greater level of fetal 
DNA in plasma compared to the DNA extracted from 
fetal cellular fraction [29,30]. 
The fetal cfDNA originates from the fetoplacental 
unit cells in the circulation or from various fetal organ 
systems. The main mechanism of fetal cfDNA release is 
supposed to be related to apoptosis of trophoblasts, as a 
result of normal aging, although an accidental breakage 
or necrosis may be the reasons as well [30]. This 
process is present continuously during pregnancy as 
early as from 5-7 weeks. The fetal fraction of cfDNA is 
lower in the earlier gestational age. Certain physiological 
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systems remove free DNA from the circulation within a 
few hours [16,31,32]. Additionally, very rapid clearance of 
fetal DNA occurs following delivery, which confirms the 
presumption that the most of fetal cfDNA in maternal 
circulation is derived from placenta [33]. 
Commercial tests for cfDNA in maternal blood have 
recently become available. Currently, a number of 
companies are trying to develop an optimal commercial 
product that could use cfDNA for fetal chromosome 
aneuploidies analysis. The absolute amount of fetal cfDNA 
is very small (less than 1mg/20ml of whole blood), which 
makes the separation of fetal cfDNA from maternal 
cfDNA technically challenging. That is why methods for 
their separation are dismissed and investigations are turned 
to the approaches that would use full cfDNA complement. 
Full cfDNA sequencing and sophisticated data analysis 
would detect abnormal amounts of chromosome specific 
DNA loci in the presence of fetal aneuploidy. The method 
of fetal cfDNA analysis was proved to be less demanding 
compared to isolation of fetal cells [7,11,31]. 
Methods of cfDNA Detection and Analysis 
The first methods which have been employed for 
gathering and analysis of cfDNA were massively parallel 
shotgun sequencing (MPSS) and targeted sequencing. Both 
approaches use next generation sequencing technique, with 
high levels of sensitivity and accuracy for reliable 
analysis of the small cfDNA amounts [2]. 
The MPSS is a quantitative test, which relies on 
detecting difference in the total amount of plasma DNA 
fragments, while not distinguishing maternal from fetal 
DNA. The MPSS technique is based on the sequencing 
of large numbers of small DNA sequences (25-36 bp in 
length) from the entire genome. In the setting of NIPT, 
it would mean the sequencing of the whole amount of 
cfDNA from maternal plasma, or tens of millions of 
short-sequences in a single run [1,2]. After the sequencing, 
the chromosomal origin of each DNA fragment is 
determined by comparison with a reference copy of the 
human genome. Fragments (or reads) are categorized by 
chromosome, as well as their number per normal reference 
chromosome, which is referred to as counting. When the 
amount of a sequence fragment exceeds the threshold for a 
normal chromosome it is considered the positive result for 
trisomy. The increase in the quantity of genetic material 
occurs due to the 50% excess of genetic material 
originating from trisomic fetus extra chromosome [1,2,34]. 
This potential difference due to aneuploidy would be 
very small as the fetal DNA represents 10% at most of 
the cfDNA fraction, and the presence of extra DNA 
material (in T21) would change total cfDNA sample for 
only 0.075%. Because of this small DNA amount 
change, a large number of reads must be made in order 
to achieve satisfying degree of confidence, making the 
whole process robust. Also, it is estimated that in order 
to return sufficient data from the clinically significant 
chromosomes (13, 18, 21, X and Y; representing only 
around 14% of the genome) approximately 25 million 
raw sequencing reads are required per sample [1,2, 
34,35]. 
The main limitation of MPSS is caused by the 
influence of GC chromosomal content on PCR 
amplification, leading to variability of the accuracy rate. 
The detection of T13 and T18 is especially challenging due 
to high GC content on these chromosomes. This issue has 
been notably reduced using novel bioinformatics 
algorithms [3437]. 
The Targeted Sequencing test selectively amplifies 
specific genomic regions (loci of interest) which are read 
and counted. This significantly reduces the total number of 
reads, and all amplified sequences are utilized compared to 
MPSS method. The focus on clinically important 
chromosomes (13, 18, 21, X and Y) should provide higher 
sensitivity and specificity for the method. Still, as with 
quantitative read, the detection rates vary, depending on the 
chromosome tested, and are highest for T21 [7,38]. Similar 
to the MPSS method, post-hoc data analysis requires 
appropriate bioinformatics platform, such as z-score with 
GC correction and an internal control [2]. 
Starting from these two first approaches of NIPT, 
different companies made the effort to develop more 
accurate, sensitive and cost effective next generation 
test. The clinical implications for all newly developed 
tests are the same - they are screening tests that use a 
sample of maternal cfDNA and positive results still 
must be confirmed by invasive testing (CVS and AC). 
One of the advanced techniques is called Digital 
Analysis of Selected Regions (DANSR). This is a targeted 
sequencing approach that initially amplifies specific 
chromosome loci of interest and then uses counting 
similar to MPSS analysis. It is coupled with post-hoc 
bioinformatics algorithm (Fetal Fraction Optimized Risk of 
Trisomy Evaluation - FORTE) that accounts for age-
related risks and fetal fraction. This approach has greater 
efficiency than MPSS alone [38]. 
Another approach - Parental Support (PS) combines 
a targeted amplification, measuring single nucleotide 
polymorphisms (SNPs), and sophisticated statistical 
analysis. In this method, the number and identity of 
alleles of preferred chromosomal loci are determined, 
after which a model set of hypotheses is calculated using 
Bayesian statistics. A probability to each hypothesis is 
estimated and considering major individual variables and 
fetal cfDNA fraction, individual risk score is provided [39]. 
In this way, the problem of chromosome amplification 
variability is omitted and similar accuracy of fetal copy 
number at chromosomes is achieved. Using PS approach it 
is easier to detect sex chromosome aneuploidies, which is 
especially important as these abnormalities represent 
nearly half of all chromosomal defects at-birth [40]. 
The results of fetal aneuploidy risk assessment using 
these methods can be provided within the first 2 weeks, 
in early pregnancy. Also, cfDNA technology testing 
appears to be highly accurate and to have very high 
sensitivity, particularly chromosome 21 aneuploidy (99%), 
and the difference compared to routine serum sample 
screening (2-4% for T21) shows its significant superiority 
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[2,6,11]. Out of aneuploidies, Down syndrome has the 
highest incidence and it is the single most common cause 
of mental retardation accompanied by serious health 
disorders. Accuracy of its detection varies depending on 
a technical approach of a company. The sensitivity and 
specificity range from 98.6-100% and 99.8-100% for 
T21, 97.2-100% and 99.7-100% for T18, 78.6-100% 
and 99.0-100% for T13 [2,36,39]. 
Proposed indications for NIPTs and cfDNA analysis 
for aneuploidy are: maternal age above 35 years, fetal 
ultrasound findings indicating an increased risk, maternal 
serum screening test showing an increased risk, previous 
pregnancy with birth defects in child, family history of 
aneuploidy, positive test result for aneuploidy, parental 
balanced Robertsonian translocation. Testing can be 
performed as early as 9 weeks’ gestation. However, 
positive results should be followed up with CVS or AC. 
What remains to be investigated is the accuracy of cfDNA 
method as NIPTs for females who are in the low risk 
population [6, 28]. 
Additionally, economic evaluation of newer NIPT 
methods is important in order to be accepted for wider 
clinical use. In the study by Song et al. [11], the cost-
effectiveness model of NIPT for high-risk women in US 
population was assessed. The results showed better T21 
detection and reduced unnecessary invasive procedures 
that lower the rate of euploid fetal losses, bringing to the 
lower total healthcare expenditures.  
The new generation non-invasive prenatal screening for 
microdeletion syndromes test (Panorama
TM
) incorporates 
maternal genotypic information, thus differentiating fetal 
genotypes in the plasma. It targets and analyses 19.488 
SNPs from chromosomes 21, 18, 13, X, and Y. 
Additionally, the targeted screening was expanded for five 
microdeletion syndromes, by including SNPs within the 
microdeletion regions-of-interest [41]. The Panorama 
Extended Panel offers a risk evaluation for the 22q11.2 
deletion (DiGeorge), 1p36 deletion, Cri-du-chat, Prader-
Willi, and Angelman deletions. The sensitivity of this test 
was assessed to be greater than 93% and specificity greater 
than 99%. The importance of this test is emphasized by 
fact that these syndromes have very low detection rates by 
traditional screening tests, the risk for microdeletions is 
independent of maternal age, and their incidence is often 
underestimated. The evaluated combined incidence of 
these syndromes using Panorama test was calculated to be 
about 1/1000, showing that the incidence of DiGeorge 
syndrome is higher than for cystic fibrosis. All these 
circumstances assert the need for inclusion of microdeletion 
syndromes in prenatal screening options [41].  
Besides the determination of the fetal aneuploidy 
risk, levels of circulating cfDNA are recognized as a 
marker of several pregnancy related complications. 
cfDNA levels were increased in preeclampsia, intrauterine 
growth restriction, preterm labor, placenta previa and 
hyperemesis gravidarum. Increased leakage of the cells is 
reported in the cases of fetal aneuploidy and 
preeclampsia. Because cfDNA levels decrease during 
diseases progression, it is suggested that they can be a 
predictive marker for early detection of these disorders 
[30, 42].  
Conclusion 
Cell-free fetal DNA in maternal blood is a valuable source 
of genetic information which has become increasingly 
available due to the progress in DNA sequencing and 
bioinformatics’ techniques. The non-invasive prenatal 
testing with cfDNA represents the new generation of 
prenatal diagnostic screening, which strives to become the 
first choice testing option due to its safety and high 
accuracy rate. The final goal is to develop a feasible and 
reliable method that could eventually replace invasive 
prenatal testing. 
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